Measuring fibrinolysis: from research to routine diagnostic assays

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 4, 2018, Pages 652-662

  Longstaff, C ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

carboxypeptidase B2; euglobulin clot lysis time; fibrin clot lysis time; plasminogen activator inhibitor 1; plasminogen activators; thromboelastometry

Indexed keywords

ANTIFIBRINOLYTIC AGENT; D DIMER; ENZYME PRECURSOR; FIBRIN; GLOBULIN; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; BIOASSAY; DRUG TARGETING; FIBRINOLYSIS; HEMOSTASIS; HIGH THROUGHPUT SCREENING; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTHROMBIN TIME; REVIEW; THROMBOSIS; VISCOELASTICITY; BLOOD; BLOOD EXAMINATION; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; THROMBOELASTOGRAPHY; THROMBOPHILIA; TIME FACTOR;

FIBRINOLYSIS; HEMATOLOGIC TESTS; HUMANS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; THROMBELASTOGRAPHY; THROMBOPHILIA; TIME FACTORS;

EID: 85042107015     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13957     Document Type: Review

References (100)

1. Astrup T. The biological significance of fibrinolysis. Lancet 1956; 271: 565–8.
2. Macfarlane RG, Biggs R. Fibrinolysis; its mechanism and significance. Blood 1948; 3: 1167–87.
3. Fearnley GR, Lackner R. The fibrinolytic activity of normal blood. Br J Haematol 1955; 1: 189–98.
4. Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 2015; 13(Suppl 1): S98–105.
5. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4–13.
6. Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol 2016; 175: 12–23.
7. Borowiecki B, Sharp AA. Trauma and fibrinolysis. J Trauma 1969; 9: 522–36.
8. Innes D, Sevitt S. Coagulation and fibrinolysis in injured patients. J Clin Pathol 1964; 17: 1–13.
9. Pellman CM, Ridlon HC, Lang Phillips L. Manifestation and management of hypofibrinogenemia and fibrinolysis in patients with carcinoma of the prostate. J Urol 1966; 96: 375–9.
10. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772–7.
11. Mackinnon S, Walker ID, Davidson JF, Walker JJ. Plasma fibrinolysis during and after normal childbirth. Br J Haematol 1987; 65: 339–42.
12. Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996; 22: 459–78.
13. Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43: 178–84.
14. Horrevoets AJG, Pannekoek H, Nesheim ME. A steady-state template model that describes the kinetics of fibrin-stimulated. J Biol Chem 1997; 272: 2183–91.
15. Brummel-Ziedins K. Models for thrombin generation and risk of disease. J Thromb Haemost 2013; 11(Suppl 1): 212–23.
16. Diamond SL. Systems biology of coagulation. J Thromb Haemost 2013; 11(Suppl 1): 224–32.
17. Bannish BE, Chernysh IN, Keener JP, Fogelson AL, Weisel JW. Molecular and physical mechanisms of fibrinolysis and thrombolysis from mathematical modeling and experiments. Sci Rep 2017; 7: 6914.
18. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5: 804–11.
19. Huish S, Thelwell C, Longstaff C. Activity regulation by fibrinogen and fibrin of streptokinase from streptococcus pyogenes. PLoS ONE 2017; 12: e0170936.
20. Verheijen JH, Mullaart E, Chang GT, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266–9.
21. Sands D, Whitton C, Merton R, Longstaff C. A collaborative study to establish the 3rd international standard for tissue plasminogen activator. Thromb Haemost 2002; 88: 294–7.
22. Thelwell C, Longstaff C, Rigsby P; Subcommittee on Fibrinolysis. An International Collaborative Study to establish the World Health Organization 4th International Standard for Plasmin (13/206): communication from the SSC of the ISTH. J Thromb Haemost 2016; 14: 215–8.
23. Longstaff C, Thelwell C, Rigsby P; SSC Fibirinolysis Subcommittee. An International Collaborative Study to establish the WHO 2nd International Standard for High Molecular Weight Urokinase: communication from SSC of the ISTH. J Thromb Haemost 2014; 12: 415–7.
24. Beebe DP, Aronson DL. An automated fibrinolytic assay performed in microtiter plates. Thromb Res 1987; 47: 123–8.
25. Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemost 2004; 2: 1416–21.
26. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost 2012; 10: 2354–60.
27. European Commission. Alteplase for injection. Monograph, European Pharmacopoeia: 2013; 2007: 1170 corrected 8.0.
28. Wohner N, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31: 2306–13.
29. Bonnard T, Law LS, Tennant Z, Hagemeyer CE. Development and validation of a high throughput whole blood thrombolysis plate assay. Sci Rep 2017; 7: 2346.
30. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 82–6.
31. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 329–37.
32. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589–91.
33. Matsumoto T, Nogami K, Shima M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost 2013; 110: 761–8.
34. Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res 2011; 127: 317–23.
35. van Geffen M, Loof A, Lap P, Boezeman J, Laros-van Gorkom BA, Brons P, Verbruggen B, van Kraaij M, van Heerde WL. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology 2011; 16: 327–36.
36. Longstaff C, for the Subcommittee on Fibrinolysis. Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15: 1044–6.
37. Rosendaal FR, Reitsma PH. Reproducibility. J Thromb Haemost 2017; 15: 833.
38. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5(Suppl 1): 116–24.
39. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590–1.
40. Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8: 2017–24.
41. Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a chandler loop mimic human arterial thrombi in structure and PAI-1 content and distribution. Thromb Haemost 1997; 77: 510–5.
42. Varju I, Longstaff C, Szabo L, Farkas AZ, Varga-Szabo VJ, Tanka-Salamon A, Machovich R, Kolev K. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost 2015; 113: 1289–98.
43. Rijken DC, Kock EL, Guimarães AHC, Talens S, Murad SD, Janssen HLA, Leebeek FWG. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–22.
44. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468–77.
45. Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. J Thromb Haemost 2014; 12: 229–36.
46. Wyseure T, Rubio M, Denorme F, Martinez de Lizarrondo S, Peeters M, Gils A, De Meyer SF, Vivien D, Declerck PJ. Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. Blood 2014; 125: 1325–32.
47. Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost 2009; 7: 1962–71.
48. Song C, Burgess S, Eicher JD, O'Donnell CJ, Johnson AD, Huang J, Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin S-Y, Ding J, Baumert J, Oudot-Mellakh T, Folkersen L, Smith NL, Williams SM, Ikram MA, Kleber ME, Becker DM, Truong V, et al. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc 2017; 6: e004918.
49. Declerck PJ, Moreau H, Jespersen J, Gram J, Kluft C. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 1993; 70: 858–63.
50. Gram J, Declerck PJ, Sidelmann J, Jespersen J, Kluft C. Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. Thromb Haemost 1993; 70: 852–7.
51. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007; 115: 996–1003.
52. Macy EM, Meilahn EN, Declerck PJ, Tracy RP. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 1993; 117: 67–70.
53. Declerck P. TAFI structure and function. J Thromb Haemost 2012; 10: e27.
54. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021–30.
55. Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi M-C. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373–9.
56. Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688–96.
57. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122–7.
58. Willemse JL, Hendriks DF. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge. Clin Chem 2006; 52: 30–6.
59. Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange P-E. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study. J Thromb Haemost 2009; 7: 49–57.
60. Neill EK, Stewart RJ, Schneider MM, Nesheim ME. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2004; 330: 332–41.
61. Heylen E, Van Goethem S, Augustyns K, Hendriks D. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: challenges overcome by a novel selective assay. Anal Biochem 2010; 403: 114–6.
62. Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26: 423–8.
63. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201–12.
64. Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products – an immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50: 591–4.
65. Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma. Br J Haematol 1995; 90: 187–94.
66. Dempfle CE, Zips S, Ergul H, Heene DL. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost 2001; 85: 671–8.
67. Dempfle CE, Korte W, Schwab M, Zerback R, Huisman MV; CARDIM Study Group. Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis. Thromb Haemost 2006; 96: 79–83.
68. Longstaff C. Shiny app for screening test exploration. RStudio Shiny Apps, 2017, Shiny app to explore test sensitivity, specificity and prevalence. https://drclongstaff.shinyapps.io/ScreeningCL, last accessed 22 December 2017.
69. Jennings I, Woods TA, Kitchen DP, Kitchen S, Walker ID. Laboratory D-dimer measurement: improved agreement between methods through calibration. Thromb Haemost 2007; 98: 1127–35.
70. Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost 2006; 95: 567–72.
71. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902–5.
72. Nuzzo R. Scientific method: statistical errors. Nature 2014; 506: 150–2.
73. Chawla DS. Big names in statistics want to shake up much-maligned P value. Nature 2017; 548: 16–7.
74. Colquhoun D. The reproducibility of research and the misinterpretation of p-values. R Soc Open Sci 2017; 4: 171085.
75. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366–75.
76. Whiting D, Dinardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89: 228–32.
77. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, Lakner M. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16: 301–10.
78. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792–7.
79. Gall LS, Brohi K, Davenport RA. Diagnosis and treatment of hyperfibrinolysis in trauma (A European Perspective). Semin Thromb Hemost 2017; 43: 224–34.
80. Balvers K, van Dieren S, Baksaas-Aasen K, Gaarder C, Brohi K, Eaglestone S, Stanworth S, Johansson PI, Ostrowski SR, Stensballe J, Maegele M, Goslings JC, Juffermans NP. Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. Br J Surg 2017; 104: 222–9.
81. Schochl H, Voelckel W, Maegele M, Solomon C. Trauma-associated hyperfibrinolysis. Hamostaseologie 2012; 32: 22–7.
82. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11: 307–14.
83. Roberts I. Tranexamic acid in trauma: how should we use it? J Thromb Haemost 2015; 13(Suppl 1): S195–9.
84. Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, Sauaia A, Cotton BA. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 2016; 222: 347–55.
85. Chapman MP, Moore EE, Moore HB, Gonzalez E, Gamboni F, Chandler JG, Mitra S, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016; 80: 16–25.
86. Hunt H, Stanworth S, Curry N, Woolley T, Cooper C, Ukoumunne O, Zhelev Z, Hyde C. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015; 2: CD010438.
87. Wikkelso A, Wetterslev J, Moller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; CD007871.
88. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5: 289–95.
89. Howard BM, Kornblith LZ, Redick BJ, Vilardi RF, Balhotra KS, Crane JM, Forde MR, Nelson MF, Callcut RA, Cohen MJ. The effects of alcohol on coagulation in trauma patients: interpreting thrombelastography with caution. J Trauma Acute Care Surg 2014; 77: 865–71; discussion 71–2.
90. ® -based individualized goal-directed coagulation algorithms: don't wait – act now! Crit Care 2014; 18: 637.
91. Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. J Thromb Haemost 2016; 14: 906–17.
92. Bajzar L, Fredenburgh JC, Nesheim M. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948–54.
93. He S, Bremme K, Blomback M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 1999; 96: 145–56.
94. He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355–61.
95. Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2005; 16: 585–96.
96. He S, Zhu K, Skeppholm M, Vedin J, Svensson J, Egberg N, Blombäck M, Wallen H. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost 2007; 98: 871–82.
97. He S, Wallèn HK, Bark N, Blombäck M. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis 2013; 35: 131–9.
98. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 345–56.
99. Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia 2006; 12: 605–14.
100. von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834–9.